Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

R. Hirsch, Fred; Varella-Garcia, Marileila; A. Bunn, Paul; A. Franklin, Wilbur; Dziadziuszko, Rafal; Thatcher, Nick; Chang, Alex; Parikh, Purvish; Rodrigues Pereira, José; Ciuleanu, Tudor; von Pawel, Joachim; Watkins, Claire; Flannery, Angela; Ellison, Gillian; Donald, Emma; Knight, Lucy; Parums, Dinah; Botwood, Nicholas; Holloway, Brian

doi:10.1200/jco.2006.06.3958

Public

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

Shared by NobleBlocks on Nov 1, 2006 • 12:00 AM UTC

Authors:

Fred R. Hirsch

Marileila Varella-Garcia

Paul A. Bunn

Abstract

Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer. We analyzed ISEL tumor biopsy samples to examine relationships between biomarkers and clinical outcome after gefitinib t...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!